GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

• Revenue in USD (TTM)100.18m
• Net income in USD-1.49bn
• Incorporated2020
• Employees1.36k

• Location
  Grail Inc1525 O'brien DriveMENLO PARK 94025United StatesUSA
• Phone+1 (650) 771-9796
• Fax+1 (302) 655-5049
• Websitehttps://www.galleri.com/